Journal
ONCOTARGET
Volume 7, Issue 23, Pages 35188-35198Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.9072
Keywords
mir-101-3p; AMPK; triple negative breast cancer; tumor metabolism
Categories
Funding
- National Natural Science Foundation of China [81472575, 81472469, 81272514, 81302318]
- Science and Technology Planning Project of Guangdong [2014J4100169, 2013B060300009, 2015B020211002, 2015B090901050, 2014A020212079]
- Science and Technology Planning Project of Guangzhou [2014J4100169, 2013B060300009, 2015B020211002, 2015B090901050, 2014A020212079]
Ask authors/readers for more resources
mir-101-3p has been reported to be a tumor suppressor and a promising therapeutic target in cancer. Recently, AMPK dysfunction has been highlighted in cancers, including breast cancer. The aim of this study is to investigate the biological roles of mir-101-3p and AMPK in breast cancer. Our research demonstrated that AMPK was up-regulated in breast cancer tissues and cell lines, especially in triple negative breast cancer (TNBC). High-expression of AMPK correlated with poor outcome in both total breast cancer and TNBC patients. Ectopic expression of AMPK improved glucose uptake, glycolysis, proliferation of TNBC cells in vitro and its tumorigenicity in vivo. AMPK was predicted to be a direct target of mir-101-3p. The luciferase reporter assay was performed to certificate this prediction. The expression of AMPK was suppressed by transfection of mir-101-3p in TNBC cells. Over-expression of mir-101-3p or knockdown of AMPK inhibited glucose metabolism and proliferation of TNBC cells in vitro. Our study provides evidence that mir-101-3p-AMPK axis could be a promising therapeutic target in TNBC targeting tumor metabolism.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available